# Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4

> **NCT00612755** · PHASE4 · COMPLETED · sponsor: **Hospital Clinico Universitario San Cecilio** · enrollment: 43 (actual)

## Conditions studied

- HIV Infections
- Hepatitis C

## Interventions

- **DRUG:** Peginterferon alfa-2a + ribavirin

## Key facts

- **NCT ID:** NCT00612755
- **Lead sponsor:** Hospital Clinico Universitario San Cecilio
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-01
- **Final completion:** 2008-01
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2008-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00612755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00612755, "Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00612755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*